Results 71 to 80 of about 3,121,151 (264)

Computation of Optimal Current References for Flux-weakening of Multi-Phase Synchronous Machines [PDF]

open access: yes, 2012
Multi-phase synchronous machines are more and more used in specific applications where high power density, low bus voltage, wide speed range and fault-tolerant capabilities are required. Due to the high number of degrees of freedom, multi-phase machines
Bassel Aslan   +13 more
core   +1 more source

Corrosion Resistance of Solution-Treated S32750 Duplex Stainless Steel in a Simulated Flue Gas Desulfurization Environment [PDF]

open access: yesCailiao Baohu
The metallurgical structure changes of S32750 duplex stainless steel during solution treatment can reduce its corrosion resistance in flue gas desulfurization environments.In this study,S32750 duplex stainless steel was solution-treated at temperatures ...
XIA Qingliang
doaj   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

open access: yesMolecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen   +9 more
wiley   +1 more source

New determination of the D0→K -π +π0 and D0→K -π +π +π - coherence factors and average strong-phase d [PDF]

open access: yes, 2014
Measurements of the coherence factors (RKππ0 and R K3π) and the average strong-phase differences (δDKππ0 and δDK3π) for the decays D0→K -π +π0 and D0→K -π +π +π - are presented.
Wilkinson, G   +35 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

The first day at school

open access: yes, 1940
1 φωτογραφία : ασπρόμ.Πρώτη μέρα σχολείο.
Ραπτόπουλος, Σ.
core  

Effect of Cr and Mo on σ- Phase Precipitation Behavior and Pitting Corrosion Resistance Properties of Ultra-Low-Carbon Dual Phase Stainless Steel

open access: yesTeshugang, 2015
The σ-phase precipitation rule in four kinds of typical ultra-low-carbon dual phase stainless steel 00Cr21Ni2Mn5N, 00Cr22Ni5Mo3N, 00Cr25Ni7Mo3N and 00Cr27Ni7Mo5N solid-solution-treaded at 1 050 ~ 1 120 °C and aged at 500 ~ 1 100 °C and the effect of σ ...
李惠   +4 more
doaj  

A New Approach to the Study of Multi-Pass Welds–Microstructure and Properties of Welded 20-mm-Thick Superduplex Stainless Steel

open access: yesApplied Sciences, 2019
Type 2507 superduplex stainless steel 20 mm in thickness was multi-pass-welded with Gas Metal Arc Welding (GMAW) and Flux-Cored Arc Welding (FCAW) processes. Recommended and higher arc energies and inter-pass temperatures were used.
Maria Asuncion Valiente Bermejo   +3 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy